Published in J Diabetes Res on April 30, 2015
Study Of Diabetic Nephropathy With Atrasentan (SONAR) | NCT01858532
Study of FG-3019 in Subjects With Type 2 DM and KD on ACEi and/or ARB Therapy | NCT00913393
Pyridorin in Diabetic Nephropathy (PIONEER) | NCT02156843
Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy | NCT01175486
Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther (2015) 0.80
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Biochemistry and molecular cell biology of diabetic complications. Nature (2001) 25.43
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 22.32
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 18.15
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med (2001) 17.24
Autophagy regulates lipid metabolism. Nature (2009) 13.33
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature (2000) 12.33
Autophagy and the integrated stress response. Mol Cell (2010) 11.21
Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med (2011) 8.54
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med (2002) 5.72
Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA (2003) 5.33
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int (2013) 5.20
Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care (2004) 4.88
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care (2008) 4.20
Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA (2002) 4.18
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Role of nrf2 in oxidative stress and toxicity. Annu Rev Pharmacol Toxicol (2013) 3.73
The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol (2008) 3.64
Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int (2013) 3.42
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med (2012) 3.38
Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A (2000) 3.36
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest (1994) 3.30
End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis (1999) 3.00
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 2.80
Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int (2003) 2.65
Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med (2003) 2.61
Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care (2004) 2.36
Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. Am J Kidney Dis (2008) 2.09
Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys (2003) 2.08
Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes (2008) 2.07
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol (2010) 2.02
NF-kappaB in renal inflammation. J Am Soc Nephrol (2010) 2.00
Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J (2000) 1.93
Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism (2003) 1.90
Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol (2003) 1.85
Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial. Am J Kidney Dis (2012) 1.83
Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A (1994) 1.82
Molecular mechanisms of diabetic kidney disease. J Clin Invest (2014) 1.80
Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.79
NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant (2004) 1.78
Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim Biophys Acta (2011) 1.67
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int (2007) 1.64
Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol (2005) 1.63
Resveratrol improves oxidative stress and protects against diabetic nephropathy through normalization of Mn-SOD dysfunction in AMPK/SIRT1-independent pathway. Diabetes (2011) 1.61
Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes (1991) 1.58
Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin Nephrol (2003) 1.56
Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A (1994) 1.54
Tumor necrosis factor induces glomerular damage in the rabbit. Am J Pathol (1989) 1.51
Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol (2007) 1.45
USRDS: the United States Renal Data System. Am J Kidney Dis (2003) 1.45
Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. J Cell Biochem (2001) 1.39
Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care (2009) 1.37
The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care (2005) 1.36
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab (2014) 1.36
Interleukin 6 is an autocrine growth factor for mesangial cells. Kidney Int (1990) 1.36
Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse. Proc Natl Acad Sci U S A (2001) 1.34
Renal pathology patterns in type II diabetes mellitus: relationship with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant (1998) 1.34
Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract (2008) 1.34
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol (2002) 1.34
Increase in diacylglycerol mass in isolated glomeruli by glucose from de novo synthesis of glycerolipids. Diabetes (1990) 1.33
Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal (2009) 1.33
Role of advanced glycation end products in diabetic nephropathy. J Am Soc Nephrol (2003) 1.32
Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol (2006) 1.31
Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol (2010) 1.30
Pirfenidone is renoprotective in diabetic kidney disease. J Am Soc Nephrol (2009) 1.29
Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol (2006) 1.29
Heparanase is essential for the development of diabetic nephropathy in mice. Diabetes (2011) 1.29
Role of nitric oxide in diabetic nephropathy. Semin Nephrol (2004) 1.28
Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II). Control Clin Trials (1999) 1.27
Role of the hexosamine biosynthetic pathway in diabetic nephropathy. Kidney Int Suppl (2000) 1.27
Tumor necrosis factor and interleukin 1 alpha increase vascular endothelial permeability. Am J Physiol (1989) 1.27
The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol (2014) 1.27
The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol (2013) 1.26
Obesity-mediated autophagy insufficiency exacerbates proteinuria-induced tubulointerstitial lesions. J Am Soc Nephrol (2013) 1.23
Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-induced podocyte injury. PLoS One (2013) 1.23
Curcumin attenuates inflammatory responses of TNF-alpha-stimulated human endothelial cells. J Cardiovasc Pharmacol (2007) 1.20
The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia (2008) 1.19
Curcumin blocks multiple sites of the TGF-beta signaling cascade in renal cells. Kidney Int (2004) 1.19
Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J Biol Chem (2003) 1.18
Sodium/glucose cotransporter 2 inhibitors and prevention of diabetic nephropathy: targeting the renal tubule in diabetes. Am J Kidney Dis (2014) 1.16
Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes (2004) 1.15
Accumulation of fructosyl-lysine and advanced glycation end products in the kidney, retina and peripheral nerve of streptozotocin-induced diabetic rats. Biochem Soc Trans (2003) 1.15
Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology (2005) 1.15
Role of AGEs in diabetic nephropathy. Curr Pharm Des (2008) 1.14
Dietary restriction ameliorates diabetic nephropathy through anti-inflammatory effects and regulation of the autophagy via restoration of Sirt1 in diabetic Wistar fatty (fa/fa) rats: a model of type 2 diabetes. Exp Diabetes Res (2011) 1.14
Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol (2007) 1.13
Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy. J Am Soc Nephrol (2014) 1.13
The role of protein kinase C activation in diabetic nephropathy. Kidney Int Suppl (2007) 1.12
Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol (2002) 1.09
Urinary tumour necrosis factor-alpha excretion independently correlates with clinical markers of glomerular and tubulointerstitial injury in type 2 diabetic patients. Nephrol Dial Transplant (2006) 1.07
Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. Scand J Urol Nephrol (2011) 1.07
Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol (2014) 1.07